4 hours ago
1
Hofmeester/iStock via Getty Images
- RBC Capital Markets has downgraded Exelixis (NASDAQ:EXEL) to sector perform from outperform, saying the shares current fairly reflect cash flows from its two marketed drugs, Cabometyx and Cometriq.
- However, the firm raised its price target to $50 from $45 (~13% upside based on July 7
English (US) ·